| Document |
Document Title |
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075809A1 |
The purpose of the present invention is to provide an antimicrobial agent having reduced allergy properties and containing recombinant psLAAO, and a method for producing this antimicrobial agent. This purpose is solved by an antimicrobia...
|
|
WO/2024/074104A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/075124A1 |
Compositions that comprise a solvent (e.g., an aqueous solvent) and a plurality of aromatic peptides that are soluble in the solvent, and non-crystalline materials formed thereof, which can be glassy and/or adhesive materials, are provid...
|
|
WO/2024/075135A1 |
The present invention relates to a stable GLP-2 peptide injectable composition, comprising GLP-2 peptide agent comprises of sodium; wherein the GLP-2 peptide agent is teduglutide or h[Gly2]GLP-2 and one or more pharmaceutically acceptabl...
|
|
WO/2024/077018A2 |
Provided herein are methods of treatment and uses involving an immunomodulatory TACI-Fc fusion protein that exhibits neutralizing activity of BAFF and APRIL (or BAFF/ APRIL heterotrimers). The provided TACI-Fc protein may include variant...
|
|
WO/2024/076285A1 |
The present invention relates to a peptide consisting of 50 amino acid residues or less and comprising the motif XG(F/L/A/V/I/M/W/C)X(L/I/V)(G/D/P) (SEQ ID NO: 1), wherein X at position (4) is independently any amino acid and X at positi...
|
|
WO/2024/031024A9 |
Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal ...
|
|
WO/2024/067531A1 |
Provided is a dual-targeting compound against FAP and integrin αvβ3. The targeting compound and a radionuclide marker thereof can synergistically target a FAP target and an integrin αvβ3 target in tumors, such that the number of and ...
|
|
WO/2024/069200A2 |
A modified protein scaffold and use thereof The invention relates to a protein comprising a limited amino acid sequence of SEQ ID NO: 115, within which a segment of the general formula Ih-mod GX1CX1VX2X3X4X5 is present where X1 is any of...
|
|
WO/2024/067756A1 |
The present invention relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by ...
|
|
WO/2024/031034A9 |
The present application relates to IL-15Rα and Fc fusion protein, IL-15 and IL-15Rα heterodimeric protein, and isolated nucleic acid molecule encoding any of the fusion protein or the heterodimeric protein, vectors and host cells compr...
|
|
WO/2024/073451A1 |
Provided herein are compositions, such as suitable for subcutaneous administration, and methods for treating ascites in an individual using a mixed V1A receptor agonist-antagonist.
|
|
WO/2024/073013A1 |
The present disclosure is directed to topical compositions and methods for the treatment and/or amelioration of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation, including Dupuytren's disease, Dupu...
|
|
WO/2024/067817A1 |
Provided is use of a neuregulin or a functional fragment thereof, or a nucleic acid encoding a neuregulin or a functional fragment thereof, or a substance for improving the yield and/or function of a neuregulin in a human body in the pre...
|
|
WO/2024/072998A1 |
The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin...
|
|
WO/2024/069192A1 |
The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transien...
|
|
WO/2024/071736A1 |
An aspect of the present invention relates to a pharmaceutical composition for the prevention or treatment of allergic diseases, containing dead cells of Streptococcus pyogenes or Streptococcal pyrogenic Exotoxin A (SpeA) protein. The de...
|
|
WO/2024/072143A1 |
One aspect of the present invention relates to: a pharmaceutical composition or a food composition for preventing, treating, or ameliorating 4R tauopathy, the composition comprising, as an active ingredient, one or more selected from the...
|
|
WO/2024/068999A1 |
The present invention provides a pharmaceutical composition comprising NFL-TBS40-63 peptide, biologically active variants or pharmaceutically acceptable salts thereof, an alanine and pharmaceutically acceptable excipients, wherein the al...
|
|
WO/2024/065651A1 |
The present invention relates to a method for loading a dimer CD24 into an HEK293 cell exosome with ADAM10 gene knocked out. By means of loading a dimer CD24 and/or ApoE protein into an HEK293 cell exosome with ADAM10 gene knocked out, t...
|
|
WO/2024/067401A1 |
The present invention relates to an ultra-long-acting platform for improving the half-life of an active molecule of a drug, which comprises immunoglobulin Fc and an advanced fatty acid chain. The present invention also relates to prepara...
|
|
WO/2024/071924A1 |
In one embodiment of the present invention, the present invention relates to an exosome and uses thereof, the exosome comprising a protein that induces cell death and a polypeptide that increases the half-life of an exosome. The exosome ...
|
|
WO/2024/071349A1 |
The present disclosure provides a suspension-type ophthalmic solution having excellent re-dispersibility. More specifically, the present disclosure provides a water-based suspension preparation containing a first component and a second c...
|
|
WO/2024/068848A1 |
The present invention features methods for treating obesity and promoting weight loss by administering to a subject a combination of a GLP-1 agonist and a GIP agonist.
|
|
WO/2024/067682A1 |
The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, ...
|
|
WO/2024/072801A1 |
Aspects of the invention are drawn to methods for treating or preventing a bacterial infection in a subject. Further aspects of the invention are drawn to methods for sensitizing an antibiotic resistant bacterial infection to an antibiotic.
|
|
WO/2024/068705A1 |
The present invention generally relates to novel protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavag...
|
|
WO/2024/067600A1 |
Provided are a glucose-responsive complex, a preparation method therefor, and use thereof. The glucose-responsive complex comprises phenylboronic acid-based polylysine and insulin with a diol structure, which are complexed with each othe...
|
|
WO/2024/066416A1 |
Provided are a CXCL-BPI fusion protein capable of being used for treating gram-negative bacterial infections, an encoding nucleic acid thereof, an expression and preparation method therefor, and use thereof for preparing a pharmaceutical...
|
|
WO/2024/067535A1 |
Provided are a small peptide and a use thereof in mucosal repair. The small peptide is selected from a basic small peptide having a sequence as shown in SEQ ID NO. 1 or SEQ ID NO. 2 or a lead small peptide containing the basic small pept...
|
|
WO/2024/071544A1 |
The present invention relates to a recombinant Fc receptor and cells comprising same, and has cleavage resistance to ADAM17 through amino acid modification of an ADAM17 cleavage site in a CD16 polypeptide, and can improve binding affinit...
|
|
WO/2024/067662A1 |
A triple-receptor agonist. The agonist comprises a polypeptide represented by formula (I), X 1X 2X 3GTX 6TSDYSIX 13X 14DX 16X 17X 18X 19X 20X 21FX 23X 24X 25LX 27X 28GGPSSGAPPPS (I), wherein X 1 is Y or H; X 2 is Aib; X 3 is Q or H; X 6 ...
|
|
WO/2024/072820A1 |
In alternative embodiments, provided are compositions, including compositions, products of manufacture and kits, and methods, for manipulating, and in particular, augmenting or increasing, T cell activity in vitro and in vivo, by for exa...
|
|
WO/2024/065059A1 |
A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comp...
|
|
WO/2024/066780A1 |
Provided are a fusion type adeno-associated virus and a gene delivery effect thereof in the lung and eyes. The fusion type adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotype AAV1 ...
|
|
WO/2024/069175A1 |
The present invention relates to clostridial neurotoxins engineered to comprise an endosomal protease cleavage site within the activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The inventi...
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/071509A1 |
The present invention may provide a pharmaceutical composition for the prevention or treatment of Alzheimer's disease, the composition containing: an amyloid-beta peptide or a nucleic acid encoding same; and rapamycin or a derivative the...
|
|
WO/2024/069176A1 |
The present invention relates to clostridial neurotoxins engineered to comprise an exogenous protease cleavage site within a modified activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The ...
|
|
WO/2024/071388A1 |
The present invention addresses the problem of providing a novel enzyme agent containing an aminopeptidase that exhibits different substrate specificity from conventional products. The present invention relates to an enzyme agent having ...
|
|
WO/2024/073397A1 |
This invention relates synthetic tetraspanin proteins comprising a heterologous protein or fragment thereof inserted within the second extracellular loop of a tetraspanin backbone, wherein the heterologous protein or fragment thereof is ...
|
|
WO/2024/073600A1 |
According to various aspects of this disclosure, the present disclosure relates to combination therapies, methods, and kits comprising MARCO blocking agents and anti-cancer agents for improvement of nanoformulated drug delivery. Further,...
|
|
WO/2024/066616A1 |
Provided is a high-affinity PD1 protein conjugate, which comprises an elastin-like polypeptide and a high-affinity PD1 protein connected to the elastin-like polypeptide. The conjugate significantly improves the biological half-life and b...
|
|
WO/2024/067785A1 |
Provided is use for the treatment of chronic hepatitis B based on an interferon synergistic immune checkpoint blocking antibody. Specifically, provided is a fusion protein, comprising a PDL1-binding polypeptide and an interferon IFN whic...
|
|
WO/2024/071370A1 |
The present disclosure provides a cyclic peptide derivative composition for treating or preventing eye disease. The present disclosure relates to: a composition comprising a compound for treating or preventing eye disease; or a pharmac...
|
|
WO/2024/073445A1 |
Provided herein are compositions, such as suitable for subcutaneous administration, and methods for modulating mean arterial pressure (MAP) in an individual using a mixed V1A receptor agonist-antagonist.
|
|
WO/2024/073528A1 |
Embodiments of the present disclosure concerns methods and compositions related to treatment using a CRISPR/Cas9/targeting antibody/gene targeting small guide RNA(sgRNA) fusion protein/ribonucleotide complex. The targeting of a polynucle...
|
|
WO/2024/067754A1 |
The present invention relates to the technical field of medicines, and relates to an auristatin drug with a high-stability hydrophilic linking unit and a conjugate thereof. Particularly, the present invention relates to a ligand-drug con...
|
